Visits: 3139, Avg visit time (secs): 224,20 Back to Index
| Page | Hits | Percent |
|---|---|---|
| 1451 | 46,22% | |
| /amylin-rfa.html | 441 | 14,05% |
| /programmes.html | 331 | 10,54% |
| /novo-t2/efsd-novo-t2-rfa08.html | 123 | 3,92% |
| /amylin/efsd-amylin-rfa09.html | 80 | 2,55% |
| /lilly/programme/efsd-lilly-rfa08.html | 75 | 2,39% |
| /msd/albert-renold/efsd-msd-arenold.html | 69 | 2,20% |
| /gsk/efsd-gsk-rfa08.html | 35 | 1,12% |
| /regulations.html | 34 | 1,08% |
| /efsd-jdrf-novo/efsd-jdrf-novo-rfa08.html | 31 | 0,99% |
| /home.html | 31 | 0,99% |
| Page | Hits | Percent |
|---|---|---|
| /exit.htm | 1493 | 47,56% |
| /sanofi-aventis cv.html | 470 | 14,97% |
| /novo-t2/efsd-novo-t2-rfa08.html | 178 | 5,67% |
| /lilly/programme/efsd-lilly-rfa08.html | 120 | 3,82% |
| /home.html | 66 | 2,10% |
| /lilly/programme/efsd-cds-lilly-rfa08.html | 66 | 2,10% |
| /lifescan/efsd-lifescan-rfa09.html | 54 | 1,72% |
| /programmes.html | 53 | 1,69% |
| /gsk/efsd-gsk-rfa08.html | 49 | 1,56% |
| /recipients.html | 48 | 1,53% |
| /msd/albert-renold/efsd-msd-arenold.html | 45 | 1,43% |